Valeant Pharma (VRX) Reports Q1 Adjusted EBITDA of $861M

Valeant Pharma (NYSE: VRX) reported GAAP Q1 EPS of $1.79, versus $1.08 reported last year. Revenue for the quarter came in at $2.11 billion, versus $2.37 billion reported last year.

• Adjusted EBITDA (non-GAAP) of $861 Million

2017 Guidance

2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75 billion from $3.55 - $3.70 billion

For earnings history and earnings-related data on Valeant Pharma (VRX) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating
• Worried the AI trade has gone too far? Evercore likes these 4 stocks